This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Roy L, Guilhot J, Martineau G, Larchee R, Guilhot F . Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005, Jul 14; [E-pub ahead of print].
Quaglia A, Parodi S, Grosclaude P, Martinez-Gracia C, Coebergh JW, Vercelli M . Differences in the epidemic rise and decrease of prostate cancer among geographical areas in Southern Europe: an analysis of differential trends in incidence and mortality in France, Italy and Spain. Eur J Cancer 2003; 39: 654–665.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pilot, P., Sablinska, K., Owen, S. et al. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 20, 148 (2006). https://doi.org/10.1038/sj.leu.2404025
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404025